Sören Müller - Senior Principal Scientist and Director, Oncology Bioinformatics, Computational Sciences

Sören Müller

Senior Principal Scientist and Director, Oncology Bioinformatics, Computational Sciences

"At Genentech we have changed the role of computational biologists from service-centered individual contributors to leads of cutting-edge programs. Exciting times lie ahead of us!"
Years at Genentech
Awards & Honors

After receiving my PhD in Molecular Bioinformatics from Goethe University in Frankfurt, I came to the U.S. for my postdoc at UCSF in 2015. This is where I first got exposed to single-cell RNA-sequencing technologies and was thrilled to see how a novel technology can entirely change our understanding of biological systems such as the tumor microenvironment (TME).

Keen do research in a collaborative, translational environment I became a Scientist in the Oncology Bioinformatics Department at Genentech in 2018. The research in my group is focused on understanding the impact of stromal and immune cell heterogeneity in the TME on cancer immunotherapy response. What I enjoy most about my work is that it is only possible through close collaboration with Scientists from the Cancer Immunology and Oncology Biomarker Development Departments. It’s a great joy to work with people every day who love science and share the same dedication towards developing immunotherapies that benefit patients.

Postdoctoral Mentor

“Tell me and I’ll forget, teach me and I may remember, involve me and I learn”. I really like this quote from Benjamin Franklin, because it reflects how I see postdoc mentorship: I would like to involve young, talented scientists in the world of computational cancer immunology. Encourage them to dive into a project, develop their own ideas, and explore their potential. It’s great to learn from trainees who have become experts in their own scientific niche and who contribute to Genentech’s outstanding scientific program.

Featured Publication

Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy.

Cancer Discov 1 February 2020; 10 (2): 232–253.

Claudia X. Dominguez, Sören Müller, Shilpa Keerthivasan, Hartmut Koeppen, Jeffrey Hung, Sarah Gierke, Beatrice Breart, Oded Foreman, Travis W. Bainbridge, Alessandra Castiglioni, Yasin Senbabaoglu, Zora Modrusan, Yuxin Liang, Melissa R. Junttila, Christiaan Klijn, Richard Bourgon, Shannon J. Turley.